Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia

International Journal of Laboratory Hematology

Volumn 34, Issue 4, 2012, Pages 432-441

  Terwijn, M ^a   Kelder, A ^a   Snel, A N ^a   Rutten, A P ^a   Scholten, W J ^a   Oussoren, Y J M ^a   Van De Loosdrecht, A A ^a   Zweegman, S ^a   Ossenkoppele, G J ^a   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; Flowcytometry; Minimal residual disease; Prognosis; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT;

ABERRANT PRIMITIVE CELL; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FRACTIONATION; CELL POPULATION; DISEASE MARKER; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

CHILD, PRESCHOOL; FALSE NEGATIVE REACTIONS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROGNOSIS; REFERENCE STANDARDS;

EID: 84862839849     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01416.x     Document Type: Article

References (13)

1. Al-Mawali A., Gillis D. & Lewis I. (2009) The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. American Journal of Clinical Pathology 131, 16-26.
2. Feller N., van der Pol M.A., van S.A., Weijers G.W., Westra A.H., Evertse B.W., Ossenkoppele G.J. & Schuurhuis G.J. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18, 1380-1390.
3. Kern W., Voskova D., Schoch C., Hiddemann W., Schnittger S. & Haferlach T. (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104, 3078-3085.
4. Maurillo L., Buccisano F., Del Principe M.I., Del P.G., Spagnoli A., Panetta P., Ammatuna E., Neri B., Ottaviani L., Sarlo C., Venditti D., Quaresima M., Cerretti R., Rizzo M., De F.P., Lo C.F., Arcese W., Amadori S. & Venditti A. (2008) Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. Journal of Clinical Oncology 26, 4944-4951.
5. San Miguel J.F., Vidriales M.B., Lopez-Berges C., az-Mediavilla J., Gutierrez N., Canizo C., Ramos F., Calmuntia M.J., Perez J.J., Gonzalez M. & Orfao A. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98, 1746-1751.
6. Venditti A., Buccisano F., Del P.G., Maurillo L., Tamburini A., Cox C., Battaglia A., Catalano G., Del M.B., Cudillo L., Postorino M., Masi M. & Amadori S. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96, 3948-3952.
7. Vidriales M.B., San-Miguel J.F., Orfao A., Coustan-Smith E. & Campana D. (2003) Minimal residual disease monitoring by flow cytometry. Best Practice & Research. Clinical Haematology 16, 599-612.
8. San Miguel J.F., Martinez A., Macedo A., Vidriales M.B., Lopez-Berges C., Gonzalez M., Caballero D., Garcia-Marcos M.A., Ramos F., Fernandez-Calvo J., Calmuntia M.J., az-Mediavilla J. & Orfao A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90, 2465-2470.
9. Leroy H., de B.S., Grardel-Duflos N., Darre S., Leleu X., Roumier C., Morschhauser F., Lai J.L., Bauters F., Fenaux P. & Preudhomme C. (2005) Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 19, 367-372.
10. Maurillo L., Buccisano F., Spagnoli A., Del P.G., Panetta P., Neri B., Del Principe M.I., Mazzone C., Consalvo M.I., Tamburini A., Ottaviani L., Fraboni D., Sarlo C., De F.P., Amadori S. & Venditti A. (2007) Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 92, 605-611.
11. Bonnet D. & Dick J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 3, 730-737.
12. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., Wheatley K., Burnett A.K. & Goldstone A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320.
13. Cloos J., Goemans B.F., Hess C.J., van Oostveen J.W., Waisfisz Q., Corthals S., de L.D., Boeckx N., Hahlen K., Reinhardt D., Creutzig U., Schuurhuis G.J., Zwaan C. & Kaspers G.J. (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20, 1217-1220.